This webpage contains promotional information relating to FyboCalm products and is intended for UK healthcare professionals only.
WEBINAR
Irritable Bowel Syndrome (IBS) is a common, chronic gastrointestinal condition now recognised as a disorder of gut–brain interaction. It is frequently encountered in community pharmacy, where many patients continue to experience symptoms despite prior treatment or self-management. IBS significantly affects quality of life and productivity, highlighting ongoing unmet needs in symptom control and patient support.
We invite you to join C+D and FyboCalm on Tuesday, 19 May, 2026 at 2pm GMT for a an insightful session designed to support pharmacy professionals in advancing their understanding and management of IBS in practice.
In this session, we will explore the evolving understanding of IBS pathophysiology, including the role of gut–brain interaction and intestinal barrier dysfunction. You’ll gain practical insights into the prevalence and burden of IBS in the UK, along with a review of current management approaches, covering lifestyle interventions, OTC options, and prescribed therapies.
What you will learn:
- How to recognise IBS as a disorder of gut–brain interaction and its relevance to symptom presentation
- How to describe the prevalence and impact of IBS in the UK and identify common unmet needs in pharmacy
- Current IBS management options
- Mechanism of action of xyloglucan in supporting intestinal barrier function
- How to apply clinical evidence to inform patient counselling, product recommendation, and referral decisions
MEET THE SPEAKERS
James Halliwell
Editor-in-Chief, C+D
Dr Elsa Lopez Pinor
Professor of Pharmacy and Pharmaceutical Technology
By completing this form you agree C+D and FyboCalm may contact you directly about industry news, products, services and events that may be of interest. This is subject to C+D’s privacy policy and FyboCalm’s privacy policy